Recombinant Human B3GALNT2 Protein, CF

R&D Systems | Catalog # 1848-GT

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems CHO-derived Recombinant Human B3GALNT2 Protein (1848-GT)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Accession Number

Q8NCR0-1

Applications

Enzyme Activity
View all B3GALNT2 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human B3GALNT2 protein
Gly35-Arg500, with C-terminal 6x His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly35

Predicted Molecular Mass

54 kDa

SDS-PAGE

55-63 kDa, reducing conditions

Activity

Measured by its ability to transfer GalNAc from UDP-GalNAc to benzyl-GlcNAc.
The specific activity is >10 pmol/min/ μg, as measured under the described conditions

Formulation, Preparation, and Storage

1848-GT
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: B3GALNT2

B3GALNT2 was first identified in 2004 through a BLAST search (1). The expressed B3GALNT2 strictly transferred GalNAc to terminal GlcNAc residue and synthesized a unique carbohydrate structure GalNAc-beta 1,3-GlcNAc, which was not known in humans or other mammals previously. The related native structure was only found later in a study of congenital muscular dystrophies (CMD), a heterogeneous group of inherited diseases characterized by the onset of muscle weakness at birth or within 2 years of life. A common subgroup within the CMDs are the dystroglycanopathies, characterized by reduced functional glycosylation of alpha -dystroglycan ( alpha -DG), a peripheral membrane protein that binds to several extracellular matrix components. Proper glycosylation of alpha -DG is critical to maintain structural integrity and force transmission between the cytoskeleton and the extracellular matrix for efficient signal transduction. Deleterious mutation in gene of B3GALNT2 was found in some of the patients of dystroglycanopathies (2). The complete structure of B3GALNT2 product was then found as an O-mannosyl trisaccharide GalNAc-beta 1,3-GlcNAc-beta 1,4-Man (3) with the mannose phosphorylated at the 6-position (4). The enzymatic activity of recombinant human B3GALNT2 was determined using a phosphatase-coupled assay (5) using GlcNAc beta 1-O-benzyl as acceptor substrate. Recombinant B3GALNT2 is also found to be highly active and specific towards O-GlcNAc and therefore is an ideal enzyme for the detection and labeling of O-GlcNAc (6). O-GlcNAc is a single GlcNAc residue attached to serine/threonine residues on nuclear and cytosolic proteins with regulatory roles from transcription, translation, cell signaling to cell cycle regulation (7).

References

  1. Hiruma, t, et al. (2004) J. Biol. Chem. 279:14087.
  2. Stevens, E. et al. (2013) Am. J. Hum. Genet. 92:354.
  3. Yoshida-Moriguchi, T. et al. (2013) Science 341:6148.
  4. Yoshida-Moriguchi, T. et al. (2010) Science 327:88.
  5. Wu, Z.L. et al. (2011) Glycobiology 21:727.
  6. Wu, Z.L. et al. (2018) https://ssrn.com/abstract=3188488
  7. Wells L, et al. (2001) Science 291:2376.

Long Name

beta-1,3-N-Acetylgalactosaminyltransferase 2

Alternate Names

B3GalNAc-T2, Beta-1,3-GalNAc-T2, EC 2.4.1, MDDGA11

Entrez Gene IDs

148789 (Human); 97884 (Mouse); 291212 (Rat)

Gene Symbol

B3GALNT2

UniProt

Q8NCR0-1

Additional B3GALNT2 Products

Product Documents for Recombinant Human B3GALNT2 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human B3GALNT2 Protein, CF

For research use only

Related Research Areas

Glycobiology-related Enzymes

Citations for Recombinant Human B3GALNT2 Protein, CF

Customer Reviews for Recombinant Human B3GALNT2 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human B3GALNT2 Protein, CF and earn rewards!

Have you used Recombinant Human B3GALNT2 Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human B3GALNT2 Protein, CF (1848-GT):

Materials
  • Glycosyltranserase Activity Kit (Catalog # EA001)
  • Assay Buffer: 50 mM HEPES, 10 mM MnCl2 (supplied in kit), pH 7.5
  • Recombinant Human B3GALNT2 (rhB3GALNT2) (Catalog # 1848-GT)
  • Benzyl 2-Acetamido-2-deoxy-beta -D-glucopyranoside (Benzyl-GlcNAc) (Santa Cruz Biotechnology Inc., Catalog # SC-221296), 25 mM stock in deionized water
  • Uridine 5'-diphospho-N-acetylgalactosamine (UDP-GalNAc) (Sigma, Catalog # U5252), 10 mM stock in deionized water
  • 96-well Clear Plate (Catalog # DY990)
  • Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
  1. Dilute 1 mM Phosphate Standard provided by the Glycosyltransferase Kit by adding 40 µL of the 1 mM Phosphate Standard to 360 µL of Assay Buffer for a 100 µM stock. This is the first point of the standard curve.
  2. Complete the standard curve by performing six one-half serial dilutions of the 100 µM Phosphate stock using Assay Buffer.  The standard curve has a range of 0.078 to 5 nmol per well.
  3. Prepare reaction mixture containing 0.4 mM UDP-GalNAc, 2 mM Benzyl-GlcNAc and 8 µg/mL Coupling Phosphatase 1 in Assay Buffer.
  4. Dilute rhB3GALNT2 to 80 µg/mL in Assay Buffer.
  5. Load 50 µL of each dilution of the standard curve into a plate. Include a curve blank containing 50 μL of Assay Buffer.
  6. Load 25 µL of 80 µg/mL rhB3GALNT2 into empty wells of the same plate as the curve. Include a Control containing 25 μL of Assay Buffer.
  7. Add 25 µL of reaction mixture to all wells, excluding the standard curve.
  8. Seal plate and incubate at 37 °C for 20 minutes.
  9. Add 30 µL of the Malachite Green Reagent A to all wells. Mix briefly.
  10. Add 100 µL of deionized water to all wells. Mix briefly.
  11. Add 30 µL of the Malachite Green Reagent B to all wells.  Mix and incubate sealed plate for 20 minutes at room temperature.
  12. Read plate at 620 nm (absorbance) in endpoint mode.
  13. Calculate specific activity:

     Specific Activity (pmol/min/µg) =

Phosphate released* (nmol) x (1000 pmol/nmol)
Incubation time (min) x amount of enzyme (µg)

     *Derived from the phosphate standard curve using 4-PL or linear fitting and adjusted for Control.

Per Reaction:

  • rhB3GALNT2:  2 µg
  • Coupling Phosphatase 1:  0.2 µg
  • UDP-GalNAc:  0.2 mM
  • Benzyl-GlcNAc: 1 mM

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes